IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703.

被引：3

作者：

Cunningham, David

Zurlo, Alfredo

Salazar, Ramon

Ducreux, Michel

Waddell, Tom Samuel

Stein, Alexander

Tournigand, Christophe

Scheithauer, Werner

Sobrero, Alberto F.

Van Cutsem, Eric

Arnold, Dirk

机构：

[1] Royal Marsden NHS Fdn Trust, London, England

[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[3] Mologen AG, Berlin, Germany

[4] Inst Catala Oncol, Early Clin Res Unit, Lhospitalet Barcelona, Spain

[5] Inst Gustave Roussy, Villejuif, France

[6] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany

[7] Hop Henri Mondor, Med Oncol, F-94010 Creteil, France

[8] Med Univ Vienna, Vienna, Austria

[9] IRCCS Osped San Martino IST, Genoa, Italy

[10] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

[11] Klin Tumorbiol, Freiburg, Germany

来源：

关键词：

D O I：

10.1200/jco.2015.33.3_suppl.tps791

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS791

引用

页数：1